As we approach the second half of 2025, a look at the year’s most notable M&A deals in biopharma signals a defining period of strategic realignment, as companies race to acquire the assets and technologies that will shape the next decade of medicine.

The 47th President's first months in office are reshaping the landscape of American medicine. A flurry of executive actions has significantly transformed the nation's health and research agenda, bringing profound implications to patients and businesses alike.

Earlier today, Eli Lilly unveiled pivotal Phase 3 data for its oral weight loss medication, orforglipron, a move that sent the company's stock soaring and signalled a potential upheaval in the multi-billion dollar weight loss market.